BA
PBYI icon

Boston Advisors’s Puma Biotechnology PBYI Stock Holding History

Boston Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-17,351
Closed -$673K – 660
2019
Q1 		$673K Buy
+17,351
New +$530K 0.03% 413
2018
Q4 		– Sell
-15,105
Closed -$693K – 655
2018
Q3 		$693K Buy
15,105
+10,675
+241% +$515K 0.03% 437
2018
Q2 		$262K Buy
+4,430
New +$257K 0.01% 597

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Boston Advisors's PBYI Position: Q2 2019 in Review

Boston Advisors sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 17,351 shares — an estimated $673K sold.

Boston Advisors first reported a position in PBYI in Q2 2018 and held it in 3 quarters. The position peaked at $693K in Q3 2018. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

  • Boston Advisors reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
  • Boston Advisors sold 17,351 Puma Biotechnology shares in Q2 2019, an estimated $673K.
  • Boston Advisors first reported a position in Puma Biotechnology in Q2 2018 and held it in 3 quarters.
  • Boston Advisors's Puma Biotechnology position peaked at $693K in Q3 2018.
  • 139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on Boston Advisors's 13F filing for Q2 2019, filed 30 Jul 2019.